Dyadic International, Inc. (NASDAQ:DYAI – Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 96,600 shares, a decrease of 19.9% from the February 13th total of 120,600 shares. Based on an average daily trading volume, of 90,700 shares, the short-interest ratio is presently 1.1 days. Currently, 0.5% of the shares of the stock are short sold.
Dyadic International Price Performance
Shares of NASDAQ:DYAI opened at $1.38 on Monday. The company’s fifty day moving average price is $1.53 and its 200-day moving average price is $1.42. The firm has a market capitalization of $40.83 million, a price-to-earnings ratio of -6.00 and a beta of 0.95. Dyadic International has a one year low of $0.93 and a one year high of $2.67. The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.15.
Hedge Funds Weigh In On Dyadic International
Institutional investors have recently made changes to their positions in the stock. Truist Financial Corp bought a new position in shares of Dyadic International in the 4th quarter worth $428,000. Inlet Private Wealth LLC bought a new position in shares of Dyadic International in the 4th quarter worth $52,000. Bank of America Corp DE increased its holdings in shares of Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares during the last quarter. Millennium Management LLC bought a new position in shares of Dyadic International during the 4th quarter valued at $28,000. Finally, Jane Street Group LLC bought a new position in shares of Dyadic International during the 4th quarter valued at $45,000. Institutional investors own 27.95% of the company’s stock.
About Dyadic International
Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.
Featured Stories
- Five stocks we like better than Dyadic International
- Utilities Stocks Explained – How and Why to Invest in Utilities
- How to Build the Ultimate Everything ETF Portfolio
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.